In AML patients, contrary to chronic lymphocytic leukemia, venetoclax – an oral, selective, small‐molecule inhibitor of BCL‐2 – is not very active as a single agent with perhaps, the exception of NPM1 or IDH mutation subgroups [25, 26]. Here, IDH1 is linked to acute myeloid leukemia.